Coegin Pharma (NGM:COEGIN) Total Stockholders Equity: kr6.05 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:COEGIN Coegin Pharma NGM:COEGIN
15 GF Score
Price kr2.90
! 3 Warning Signs
View Full Analysis

What is Coegin Pharma Total Stockholders Equity?

Coegin Pharma NGM:COEGIN -3.33% 15 Total Stockholders Equity is kr6.05 Mil as of Jun. 2026. GuruFocus rates NGM:COEGIN with a GF Score™ of 15/100. The stock has 3 warning signs investors should review.

Coegin Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was kr6.05 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Coegin Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was kr0.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Coegin Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Coegin Pharma  (NGM:COEGIN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Coegin Pharma's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.054-0)/28.591
=0.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Coegin Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 6.054
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma Total Stockholders Equity Related Terms

Coegin Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Coegin Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coegin Pharma Total Stockholders Equity Chart

Coegin Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 20.07 21.01 6.75 25.26 4.74

Coegin Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.70 11.65 4.74 11.97 6.05
NGM:COEGIN
15GF Score
Coegin Pharma NGM:COEGIN
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr6.05 Mil mean?
Coegin Pharma (NGM:COEGIN) has a Total Stockholders Equity of kr6.05 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Coegin Pharma and its competitors.
Is Coegin Pharma's Total Stockholders Equity too high?
Coegin Pharma's current Total Stockholders Equity is kr6.05 Mil. Overall, Coegin Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Total Stockholders Equity compare to VRTX and REGN?
Coegin Pharma's Total Stockholders Equity of kr6.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Coegin Pharma and its competitors. Coegin Pharma's current Total Stockholders Equity is kr6.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Total Stockholders Equity of kr6.05 Mil. The current Total Stockholders Equity is kr6.05 Mil. Coegin Pharma's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Total Stockholders Equity is kr6.05 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Coegin Pharma Business Description

Other Exchanges 7Z6:Germany
Address c/o Medicon Village, Lund, SWE, 223 81
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
15GF Score

Get the complete analysis for NGM:COEGIN

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.90
Price